Endpoints News 生物医药· Lei Lei Wu·· 10 天前精选AI 评分65
Beam 表示基因编辑疗法在二期临床试验中取得成功
Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study
AI 导读
Beam Therapeutics 宣布其基因编辑疗法在二期临床试验中取得成功,可能成为治疗镰状细胞病的第三种单次疗法。
推荐理由
详细报道了基因编辑疗法在二期临床试验中的成功结果,为该疗法的进一步发展提供了重要依据。
正文 · 原文
Beam Therapeutics announced Tuesday that its base-edited sickle cell therapy succeeded in a clinical trial, meaning a third one-time therapy for the disease may soon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news